ArticleCureus2025
Successful Management of Pregnancy in a Patient With Fabry Disease Receiving Continuous Enzyme Replacement Therapy: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fabry disease is an X-linked lysosomal storage disorder characterized by deficient or reduced α-galactosidase A activity, resulting in the progressive accumulation of globotriaosylceramide in vascular endothelial cells. Although traditionally considered an X-linked recessive disorder predominantly affecting the male population, the heterozygous female population frequently develops significant clinical manifestations. Pregnancies complicated by Fabry disease are associated with an increased risk of hypertensive disorders of pregnancy and exacerbation of Fabry disease-specific symptoms. While enzyme replacement therapy and chaperone therapy have revolutionized disease management, the rarity of Fabry disease has precluded the establishment of consensus guidelines for pregnancy management. We present a case of successful maternal and perinatal management in a pregnant woman with Fabry disease who maintained α-galactosidase A therapy throughout pregnancy, accompanied by a comprehensive literature review of 21 additional cases. Our review revealed predominantly favorable outcomes with enzyme replacement therapy during pregnancy, with lower rates of proteinuria (9.1% vs. 37.2%, p = 0.01) compared to historical Fabry disease cases without enzyme replacement therapy. Common prepregnancy symptoms included proteinuria (45.5%), limb pain (40.9%), and acroparesthesia (31.8%), with symptom exacerbation during pregnancy including renal dysfunction (13.6%) and limb pain (9.1%) despite continued therapy. Pregnancy complications included hypertensive disorders (13.6%), preeclampsia (9.1%), and preterm delivery (9.1%). No congenital anomalies were reported among the newborns. Our findings suggest that enzyme replacement therapy can be safely maintained during pregnancy with careful monitoring and multidisciplinary management involving Fabry disease specialists for optimal maternal and fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.